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Introduction
Congenital Central Hypoventilation Syndrome (CCHS) is a 
breathing disorder caused by a decreased sensitivity to hypercapnia 
and hypoxia in the brainstem. This leads to hypoventilation, especially 
during non-REM sleep in most patients, but also during wakeful states 
in more severely affected individuals. Patients with CCHS often present 
with shallow breathing leading to cyanosis within the first hours of life, 
but can in milder cases go undiagnosed for years. Due to the carbon 
dioxide retention that frequently develops in these patients, breathing 
support or mechanical ventilation is often necessary [1-6].
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Abstract
Introduction: Neuroblastoma (NB), Hirschsprung disease (HSCR), Congenital Central Hypoventilation 
Syndrome (CCHS), clinically referred as the NB-HSCR-CCHS cluster, is genetic disorders linked to mutations in the 
PHOX2B gene on chromosome 4p12. 
Specific aim: The specific aim of this project is to define the PHOX2B gene mutations as the genomic basis for 
the clinical manifestations of the NB-HSCR-CCHS cluster.
Patient: A one day old male patient presented to the JUMC neonatal ICU due to abdominal distention, vomiting, 
and severe apneic episodes. With the preliminary diagnosis of the NB-HSCR-CCHS, the blood and tissue samples 
were acquired from the child, as well as from the child’s parents. All procedures were pursued in accordance with 
the Declaration of Helsinki, with the patient’s Guardian Informed Consent and the approval from the Institutional 
Review Board. 
Genetic/genomic methods: Karyotyping was analyzed based upon Giemsa banding. The patient’s genomic 
DNA was extracted from peripheral blood and amplified by polymerase chain reaction. Direct microfluidic Sanger 
sequencing was performed on the genomic DNA amplicons. These procedures were pursued in addition to the 
routine clinical examinations and tests.
Results: G-banding showed the normal 46 XY karyotype. However, genomic sequencing revealed a novel, 
heterozygous deletion (8 nucleotides (c.699-706, del8) in exon 3 of the PHOX2B gene on chromosome 4. This led 
to the frame-shift mutation and malfunctioning gene expression product.
Conclusion: Herein, we report a novel PHOX2B gene mutation in the patient diagnosed with the NB-HSCR-
CCHS cluster. The resulting gene expression product may be a contributor to the clinical manifestations of these 
genetic disorders. It adds to the library of the mutations linked to this syndrome. Consequently, we suggest that 
screening for the PHOX2B mutations becomes an integral part of genetic counseling, prenatal screening, and 
preparing supportive therapy upon delivery.
Hirschsprung’s Disease (HSCR) is a motor disorder of the 
gastrointestinal tract [7]. It is caused by failure of neural crest cells 
to properly migrate during intestinal development. The aganglionic 
intestinal segment is unable to relax, which leads to functional 
obstruction [8-11].
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Neuroblastoma (NB) is a neuroendocrine tumor that arises from 
neural crest cells. It is the most common neoplasm in infancy and the most 
common extracranial solid cancer in childhood. The vast majority of cases 
are non-familial. However, in rare cases of familial neuroblastomas, they 
have been shown to carry mutations in Anaplastic Lymphoma Kinase 
(ALK), Paired-like homeobox 2b (PHOX2B), and KIF1B genes [12-14].
During fetal development a reciprocal balance between expression 
of PHOX2B and SOX10 is responsible for maintaining the processes of 
neuronal and glial differentiation of the neural crest. Central Congenital 
Hypoventilation Syndrome (CCHS), Hirschsprung’s Disease (HSCR) 
and Neuroblastoma (NB) are categorized as neurocristopathies [15-
21]. These are genetic disorders caused by aberrant development of 
neural crest cells. 90% of the patients with CCHS are heterozygous for 
mutations in exon 3 of the paired-like homeobox 2B gene, (PHOX2B) 
on chromosome 4. It is responsible for encoding the transcription 
factor required for neuronal development. Collectively, they are often 
referred to as the NB-HSCR-CCHS cluster [22]. Interestingly, Sudden 
Infant Death Syndrome (SIDS) has also been recently linked to this 
gene’s mutations.
In healthy individuals, the PHOX2B gene has an exon coding for 20 
alanine repeat sequence. Gene mutations, that expand this region, are 
known as polyalanine repeat mutations (PARMs). They are responsible 
for over 90% of PHOX2B mutations. Alternatively, missense, nonsense, 
or frameshift mutations in the PHOX2B gene result in non-polyalanine 
repeat mutations (nPARMs). While these mutations account for less 
than 10% of cases, they lead to a more severe phenotype and most 
aggravated clinical manifestations.
Herein, we describe a novel nPARMs - mutation deletion in exon 
3 (c.699-706, del8) of the PHOX2B gene located on the chromosome 
4p12, in the male neonate, who has been clinically diagnosed with the 
CCHS, HSCR and NB, also referred as the NB-HSCR-CCHS cluster.
Patient’s Clinical Presentation
A 2900 g male was born at 41 weeks gestation by vaginal delivery 
on December 4, 2010, to a 24 years old Gravida II Para II mother. The 
boy appeared healthy at birth with APGAR scores of 5 and 8 at the 
first and fifth minute, respectively. The pregnancy was complicated by 
polyhydramnios.
The patient was admitted to the Jagiellonian University Medical 
Center (JUMC) American Children’s Hospital in Prokocim, Poland, 
European Union, on the second day of his life (Figures A-F). The parents 
were presented with the Patient’s Bill of Rights in accordance with the 
Declaration of Helsinki and signed the Guardian Informed Consent. 
All the procedures that followed were approved by the Institutional 
Review Board. 
Prenatal screening was offered in the next pregnancy, but was 
declined. The male newborn, Gravida III Para III, has shown no 
symptoms of neurocristopathies.
Materials and Methods
Ultrasonography (USG)
Ultrasonography was performed using the EnVisor C; Philips 
Medical Systems Nederland BV (Best, the Netherlands). The probe 
used: was Micro convex at the frequency 10 MHz. 
X-ray and computed tomography (CT)
X-ray imaging followed by Computed Tomography (CT) were 
pursued on the General Electric Light Speed VCT. The contrast agent 
administered for CT was Ultravist 300 at 2-3 ml/kg. The images were 
analyzed using Advantage Windows software from the General Electric 
(Milwaukee, WI, USA).
Capillary electrophoresis
Analysis was performed on the Next Generation Capillary 
Electrophoresis System: The 3500 Series Genetic Analyzers ABI 3500 
(Life Technologies, Waltham, MA, USA, Cat#: 4404312).
Histopathology
Multiple intestinal biopsies were taken. The samples were fixed 
in buffered formalin solution. They were dehydrated and embedded 
in paraffin. The tissues in paraffin blocks were cut into 3 micrometer 
thick sections. For patomorphology, the sections were stained with 
Hematoxylin and Eosin. For immunocytochemistry, the sections 
were labeled with antibodies against Neuronal Specific Enolase 
(DAKO) followed by reporters: HRP based EnVision+ System with 
DAB+Substrate-Chromogen (DAKO). The immunolabelled sections 
were also counterstained with Hematoxylin and Eosin. The samples 
were mounted and photographed. 
Blood tests
Blood for routine testing was drawn upon the admission to the hospital 
and followed up daily according to the sterile clinical procedures. Blood 
was also evaluated for neuron specific enolase and ferritin. 
Urine tests
Concentrations of catecholamines in urine were determined by 
electrocheminal detection on high pressure liquid chromatography 
(HPLC). 
Karyotyping
2 ml of blood was collected into tubes with Heparin (Vacucol 
Lithium Heparin, Medlab Products). Then it was cultured for 72 
h in the incubator (Heraeus, Hera cell, Germany, EU). The culture 
medium consisted of 2 ml of the Fetal Calf Serum (Biowest, South 
America), 8 ml of RPMI (Wytwórnia Surowic i Szczepionek Biomed, 
Lublin, Poland, EU) and 0,8 ml of LF-7 (Biomed, Krakow, Poland, 
EU). For synchronization, after 72 h, 4 drops of colchicine was added 
(KaryoMAX COLCEMID Solution, Gibco, Grand Island, New York, 
USA). The cultures were centrifuged for 8 minutes at 1200 rpm at the 
room temperature. The supernanatant was discarded. The cells were 
resuspended in 3% KCl and incubated for 30 minutes at 30 degrees 
C. The cells were fixed in the 3:1 mixture of acetic acid and methanol 
(Chempur, Piekary Silesia, Poland and EU). The slide carrying the 
chromosomes were immersed in a preparation of trypsin preparation 
(0.16 g of trypsin dissolved in 100 ml of KH2PO4 and Na2HPO4 x 12 
H2O, mixed in the ratio 1: 1) for one second, and then rinsed in ice-
water. The samples were stained for 1min with Wright’s eosin methylene 
blue solution and sealed with mounting medium. [23] The mounts were 
recorded with the Nikon microscope.
Genomics
The genomic DNA was extracted from peripheral blood with 
the use of a Master Pure DNA Purification Kit (Epicentre-Illumina, 
Eindhoven, NL, EU, Cat#: MCD85201) according to the manufacturer’s 
instructions. Polymerase chain reaction based amplification was 
performed according to the guidelines facilitating down-stream Sanger 
Sequencing [24,25].
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Sanger sequencing (Life technologies Sanger sequencing workflow) 
was performed on the amplicons after PCR with the use of a Big Dye 
Terminator Kit (Life Technologies-Analytik, Warsaw, Poland, EU, Cat#: 
4337455). 
Sequencing primers: The primers were designed based upon the 
GenBank sequence using the National Institutes of Health GST Prime 
software (Bethesda, MD, USA) and synthesized by Genomed S.A 
(Warsaw, Poland, EU) (Table 1).
Results
Upon the admission, the neonate patient presented with 
generalized muscular hypotonia and dysmorphic facial features, 
including downward-slanting palpebral fissures, prominent forehead, 
and hypoplastic facial bones with retro- and micrognathia. The patient 
failed to pass meconium and presented with abdominal distention, 
vomiting and greenish gastric residuals (Figure 1). 
Upon the initial screening, findings of cranial and abdominal 
ultrasound were unremarkable. Radiologic examination suggested 
intestinal atresia or long segment HSCR. Furthermore, serial abdominal 
X-rays revealed dilated proximal intestinal loops with a microcolon 
(Figure 2). A barium enema contrast study showed microcolon. 
The infant underwent an open laparotomy with resection of the 
colon and formation of an ileostomy. 
The tissue samples were acquired during the first laparotomy. The 
microscopic examination of the resected colon showed aganglionosis 
of the entire intestinal tract. This resulted in the clinical diagnosis of 
Hirschsprung’s Disease (HSCR).
The specific tests for neuronal specific enolase in serum revealed its 
increased level: 40.37 ng/ml. The value for ferritin reached 487.2 µg/l. 
Urine was collected daily for measurements of the catecholamines’ 
metabolites, as further metanephrine and normetanephrine are both 
metabolized to vanillylmandelic acid. These values were increasingly 
elevated in consecutive days: 16.295; HVA: 32.993; 5HIAA: 22.836; 
Normetanephrine: 1.851 mcg/mg creatinine (121-946 mcg/g 
creatinine); Metanephrine: 0.219 mcg/mg creatinine (82-418 mcg/g 
creatinine); 3 Metoksytyramine: 0.621 mcg/mg creatinine. These results 
furthered the diagnosis of Neuroblastoma.
Due to recurrent intestinal obstruction and an aggravated clinical 
status, CT scans were performed. They showed two calcified tumor 
masses located bilaterally in the thoracolumbar paravertebral area, and 
one calcified mass in the left suprarenal area extending from the renal 
vessels to the abdominal aorta (Figure 3). The ROI liver scan revealed 
multiple foci of metastases.
The recurrent intestinal obstruction prompted the second 
Forward primer 5’ctgcttcaccgtctctccttcc
Reverse primer 5’-tacccgctcgcccactcg
Table 1: PCR primer sequences.
Figure 1: A-B. The facial features of the patient. Notice downward-slanting 
palpebral fissures, prominent forehead, and hypoplastic facial bones with retro- 
and micrognathia. C-F. The overall appearance of the patient. Notice the scars 
after laparotomy.
Figure 2: A projection from the abdominal X-ray performed after the patient’s 
first laparotomy. It reveals the small bowel distention and microcolon.
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laparotomy on the 17th day of life. It was prompted by radiologic 
findings of abdominal, calcified masses. 
During the surgery, the biopsies of the suprarenal tumor and liver 
masses were acquired for histopathology and immunocytochemistry. 
The results supported the diagnosis of Neuroblastoma (Schwannian 
stroma poor) poorly differentiated subtype (Figure 4). 
The baby experienced two apneic episodes. These were managed 
with oxygen supplementation and nasal CPAP. On the third day of 
life, the infant was intubated and mechanical ventilation was started 
using Synchronized Intermittent Mandatory Ventilation (SIMV). 
During hospitalization the patient experienced transient episodes of 
hypoxia with saturation as low as 60% and hypercapnia reaching 145 
mm Hg. Every attempt of extubation failed and resulted in severe 
hypoventilation; therefore ventilator dependence was assured. 
Based upon the blood draw and cell culture propagation, 
karyotyping was performed. It revealed the normal 46XY karyotype 
with no alterations (Figure 5).
Read-out of the Sanger sequencing of the patient’s and parent’s 
genomic DNA was performed after nested PCR amplification and 
amplicons’ sequencing (Figure 6). It shows the portions of exon 3 of the 
PHOX2B gene, c.689-711. The gene sequencing of the genomic DNA 
revealed a heterozygous deletion: 8 nucleotides (c.699-706, del8) in 
exon 3 of the PHOX2B gene on chromosome 4. Therefore, it resulted in 
the frameshift mutation in the patient’s DNA. 
Prompted by discovery of the nPARM mutation in the PHOX2B 
in the offspring, the blood samples were also acquired from the 
parents. The sequencing was also performed on the genomic 
DNA using the same methodology, as for the patient. The results 
indicated that the parents had the wild type PHOX2B. Therefore, it 
was concluded that the deletion present in the patient, occurred de 
novo. 
Figure 3: A section from the abdominal CT conducted during the third week of 
life. It highlighted calcified liver mass.
Figure 4: A microscopic image of the biopsy taken during the second 
laparotomy after sectioning and staining with Hematoxylin and Eosin. The 
image facilitates diagnosis of Neuroblastoma (Schwannian stroma poor) poorly 
differentiated subtype composed of undifferentiated neuroblastic cells with 
recognizable neuropil (primary magnification x 400).
Figure 5: Chromosomes’ spreading revealed the normal 46XY karyotype with no 
alterations. The patient’s information has been suppressed (upper right corner).
Figure 6: Read-out of the Sanger sequencing of the patient’s and parent’s
genomic DNA. It shows the portions of exon 3 of the PHOX2B gene, c.689-
711.
Top: the sequence of the patient’s PHOX2B gene revealing the heterozygous
frameshift mutation c.699-706 del 8 (genomic sequence accession number
ENSG00000109132).
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Gene’s Summary
Gene: PHOX2B 
Description: Paired-like homeobox 2b [Source: HGNC Symbol; 
Acc: HGNC: 9143]
Synonyms: NBPhox, PHOX2B, PMX2B
Location: Chromosome 4: 41,744,082-41,748,970 reverse strand
INSDC coordinates: Chromosome: GRCh38:
CM000666.2:41744082:41748970:1
About this gene: This gene has 2 transcripts (splice variants), 55 
orthologues, 14 paralogues, is a member of 1 Ensembl protein family 
and is associated with 7 phenotypes.
CCDS: This gene is a member of the Human CCDS set: CCDS3463.1 
UniProtKB: This gene has proteins that correspond to the following 
Uniprot identifiers: Q99453 
RefSeq: Overlapping RefSeq Gene ID 8929 matches and has similar 
biotype of protein coding 
LRG: LRG_513 provides a stable genomic reference framework for 
describing sequence variations for this gene 
Ensembl version: ENSG00000109132.6 
GRCh37 assembly: This gene maps to 41,746,099-41,750,987 in 
GRCh37 coordinates. 
View this locus in the GRCh37 archive: ENSG00000109132 
Gene type: Known protein coding
Clinical Epilogue
Due to the exceedingly poor prognosis, after ethical considerations, 
parents made the decision not to initiate invasive cancer therapy.
The patient was kept sedated on breathing support until he died of 
cardiac arrest on the 50th day of his life.
Discussion
The PHOX2B gene encodes a highly conserved homeodomain 
transcription factor important in the development and migration 
of neural crest cells. Mutations in this gene may lead to a variety of 
autonomic nervous system defects, including CCHS, HSCR and NB, 
as seen in our patient. More than 90% of patients with CCHS will be 
heterozygous for a mutation in this gene, while polyalanine repeat 
expansion mutations (PARMs) account for over 90% of them. A larger 
number of polyalanine repeats correlates with a more severe clinical 
phenotype, with the constellation of both CCHS and HSCR commonly 
being caused by an expansion of +6 or +7 alanines. A +5 PARM is 
being described as prevalent in the patient population diagnosed 
with late-onset central hypoventilation syndrome. The remaining 
PHOX2B mutations are classified as non-PARMs, including missense, 
nonsense and frameshift mutations, which are almost all de novo 
mutations with rare exceptions. This has been reported to result in a 
more severe phenotype, and is much more frequently associated with 
neuroblastomas. 
Depending on the type of mutation involved, the clinical presentation 
of PHOX2B mutations can range from being completely asymptomatic 
at birth, to severe CO2 retention, as seen in our patient. Other patients 
may present at an older age, with cyanosis, edema, and signs of right-
sided heart failure as the first indications of CCHS. Still, others may 
present with unexplained apnea or an apparent life-threatening event, 
or some may even die and be categorized as having sudden infant death 
syndrome (SIDS). Late-onset central hypoventilation syndrome has 
also been described, for which symptoms present in late childhood or 
adulthood. The heterogeneity in expression and clinical presentation 
creates great difficulties in correctly diagnosing the PHOX2B mutations, 
which may lead to delays in the initiation of proper treatment. Given 
the extreme clinical variability, it is possible that the prevalence of 
congenital central hypoventilation syndrome in the general population 
is much higher than previously estimated. 
Futuristically thinking, since this single gene’s mutations are linked 
to many genetic disorders, then potentially the PHOX2B gene may 
become an ideal target for gene therapy trials.
Conclusion
Herein, we report a novel mutation in the PHOX2B gene in the 
patient diagnosed with the NB-HSCR-CCHS cluster. The resulting gene 
expression product may be a contributor to the clinical manifestations 
of these genetic disorders. It adds to the library of the mutations linked 
to this syndrome. Consequently, testing for the PHOX2B mutation 
could be performed on circulating fetal cells ahead of delivery and 
should be performed in intubated infants, when breathing difficulties 
occur upon extubation. Therefore, we suggest that screening for a 
PHOX2B mutation could become integral parts of genetic counseling, 
prenatal screening, and preparing supportive therapy upon delivery. 
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